1. Health technology

  2. •

    Pharmaceuticals: major
Galderma Group AG

Galderma Group AG

173.00
EUR
-1.00
(-0.57%)
41.00BMarket Cap
Galderma Group AG
MIL:1GALD
(Euronext Milan)

Recent

price

173.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
CHF
13.23
14.87
14.58
16.96
17.62
- -
Revenue per Share
-0.59
-0.38
-0.2
0.88
2.06
- -
Basic EPS, GAAP
0.75
0.43
0.58
1.86
3.98
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.14
- -
Dividend per Share
- -
- -
19.01
29.77
27.53
27.53
Book Value per Share
- -
- -
-16.58
-8.28
-5.47
-5.47
Tangible Book Value per Share
238
238
238
238
236
236
Basic Weighted Avg Shares
3,142
3,533
3,463
4,028
4,153
- -
Sales/Revenue/Turnover
10.37
10.62
14.84
15.27
16.71
- -
Operating Margin (%)
231
257
232
266
256
- -
Depreciation Expense
-141
-91
-48
210
486
- -
Net Income, GAAP
- -
- -
618.18
25.48
4.08
- -
Effective Tax Rate (%)
-4.48
-2.58
-1.38
5.2
11.7
- -
Profit Margin (%)
- -
- -
38
286
303
303
Working Capital
- -
- -
4,076
2,471
2,131
2,131
LT Debt
- -
- -
4,516
7,067
6,457
6,457
Total Equity
- -
- -
- -
4.74
6.85
- -
Return on Invested Capital (%)
- -
- -
- -
4.94
6.8
- -
Return on Capital (%)
- -
- -
- -
3.62
7.18
- -
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
33
45
52
LT Borrowings
2,392
2,138
2,044
LT Finance Leases
79
73
87
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
237
235
235
Market Capitalization
- -
26,981
38,169

Working Capital

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,672
1,514
1,931
Cash, Cash Equivalents & STI
415
363
618
Accounts Receivable, Net
684
679
708
Inventories
366
398
416
Total Current Liabilities
1,386
1,387
1,628
Payables & Accruals
- -
- -
- -
ST Debt
33
45
52
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-8.63%
Free Cash Flow
- -
- -
112.1%
Net Income, GAAP
- -
- -
131.79%
Sales/Revenue/Turnover
- -
- -
3.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3,463
2024
- -
- -
- -
- -
4,028
2025
- -
- -
- -
- -
4,153

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.2
2024
- -
- -
- -
- -
0.88
2025
- -
- -
- -
- -
2.06

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.14
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business